Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 428,430 | 966,777 | 2,115,869 | 1,502,648 | 835,080 |
| Marketable Securities | 1,247,820 | 1,022,597 | 0 | 435,923 | 289,668 |
| Receivables | 400,327 | 214,628 | 152,990 | 101,340 | 90,879 |
| Inventories | 322,859 | 203,968 | 186,212 | 231,961 | 171,379 |
| Other current assets | 179,895 | 149,891 | 149,028 | 213,324 | 81,907 |
| TOTAL | $2,579,331 | $2,557,861 | $2,604,099 | $2,485,196 | $1,468,913 |
| Non-Current Assets | |||||
| PPE Net | 227,154 | 180,037 | 191,156 | 190,430 | 129,620 |
| Intangibles | 0 | 0 | 14,239 | 13,628 | 12,497 |
| Other Non-Current Assets | 458,091 | 390,468 | 338,480 | 295,464 | 211,792 |
| TOTAL | $685,245 | $570,505 | $543,875 | $499,522 | $353,909 |
| Total Assets | $3,264,576 | $3,128,366 | $3,147,974 | $2,984,718 | $1,822,822 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 105,483 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 164,918 | 95,875 | 76,741 | 111,090 | 68,094 |
| Accrued Expenses | 314,997 | 418,996 | 271,697 | 193,553 | 185,527 |
| Other current liabilities | N/A | N/A | 15,051 | 22,139 | 7,843 |
| TOTAL | $653,659 | $619,604 | $452,733 | $416,026 | $264,767 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,132,515 | 1,544,292 | 1,096,876 | 992,493 | 681,900 |
| Deferred Revenues | 50,416 | 89,244 | 89,244 | 89,244 | 3,303 |
| Other Non-Current Liabilities | 182,065 | 94,520 | 96,112 | 150,952 | 57,968 |
| TOTAL | $1,751,580 | $2,123,812 | $1,767,232 | $1,806,933 | $739,868 |
| Total Liabilities | $2,405,239 | $2,743,416 | $2,219,965 | $2,222,959 | $1,004,635 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 93,855 | 87,982 | 87,150 | 79,421 | 77,777 |
| Common Shares | 9 | 9 | 9 | 8 | 8 |
| Retained earnings | -4,446,213 | -3,910,236 | -3,206,748 | -2,848,129 | -2,294,001 |
| Other shareholders' equity | 918 | -1,664 | -20 | 3 | 50 |
| TOTAL | $859,337 | $384,950 | $928,009 | $761,759 | $818,187 |
| Total Liabilities And Equity | $3,264,576 | $3,128,366 | $3,147,974 | $2,984,718 | $1,822,822 |